Market Overview

Shares of Intercept Pharma Rise as BofA Sees US, EU Regulators Giving A Thumbs Up

Share:
Related ICPT
Intercept Shares Turn Negative Following Mid-Day Sell Rating From Cantor
10 Biggest Mid-Day Losers For Thursday
New Approvals Provide Reason For Optimism In 2016 (Seeking Alpha)

On Monday, Bank of America released a bullish note on Intercept Pharmaceuticals (NASDAQ: ICPT). Shares trended higher throughout the session, spiking over the $440 level just minutes before the bell. The stock closed up nearly 8 percent.

Analyst Rachel McMinn believes the company should see FDA and EU regulators' support on using reversal of steatohepatitis, with no fibrosis progression, as surrogate histologic endpoint. Intercept's endpoint is to approve non-alcoholic steatohepatitis (NASH) drugs for the pre-cirrhotic population, according to the BofA analyst.

McMinn believes that regulators will need Phase 3 studies for approval, but regulators won't require CV outcomes data prior to approval.

Latest Ratings for ICPT

DateFirmActionFromTo
Jul 2016Cantor FitzgeraldInitiates Coverage onSell
May 2016Cowen & CompanyMaintainsOutperform
May 2016JMP SecuritiesMaintainsMarket Outperform

View More Analyst Ratings for ICPT
View the Latest Analyst Ratings

Posted-In: Analyst Color News FDA Analyst Ratings

 

Related Articles (ICPT)

View Comments and Join the Discussion!